|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Therapy with angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) is a mainstay of treatment for heart failure (HF), diabetes mellitus (DM) and chronic kidney disease (CKD).
|
31663151 |
2020 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
We conducted a retrospective cohort study including consecutive adult patients followed at the HF clinic of a tertiary care center who had already been on an angiotensin-converting enzyme inhibitor (ACEI) or an angiotensin receptor blocker (ARB).
|
31665724 |
2020 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Beta-adrenergic blockers and angiotensin converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs) have been the mainstay of treatment for heart failure patients with reduced left ventricular ejection fraction for many years.
|
31008768 |
2020 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
HF drug exposure-beta blockers (BB), angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARBs), aldosterone antagonists (AA), diuretics, digoxin, or ivabradine-was assessed quarterly using a Proportion of Days Covered ≥ 66% (≥ 60 days out of the 90 days of the quarter), by considering HF drugs individually or in combination.
|
31637454 |
2020 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to assess the association between prescribed ACE inhibitors and dietary sodium density in patients with HF.
|
30855313 |
2020 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Classic RAS blockers such as angiotensin converting enzyme inhibitors (ACE-I) and angiotensin receptor blockers (ARB) may prevent AF by affecting the accumulation of the EAT, representing a useful therapeutic strategy for preventing AF especially in patients with heart failure and known left ventricular dysfunction.
|
31375968 |
2020 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Until recently, the combination of beta-blockers, reninangiotensin system inhibitors (angiotensin converting enzyme (ACE)-inhibitors or angiotensin receptor blockers (ARBs)), and mineralocorticoid receptor antagonists (MRAs) formed the foundation of "triple therapy" for heart failure.
|
31736333 |
2020 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
All study participants did not have prior heart failure or use of angiotensin-converting enzyme inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs) up to 5 years prior.
|
31843974 |
2020 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Moreover, the pathological involvement of Angiotensin-converting enzyme 1 (ACE1)/angiotensin II (Ang II)/angiotensin II type 1 (AT1) axis and beneficial ACE2/Ang (1-7)/Mas receptor axis also shows protective role via Gi βγ, during heart failure these receptors get desensitized or internalized due to increase in the activity of G-protein-coupled receptor kinase 2 (GRK2) and GRK5, responsible for phosphorylation of G-protein-mediated down regulatory signaling.
|
31785110 |
2020 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Inhibition of RAAS using angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs) have shown to significantly reduce morbidity and mortality due to HF.
|
31433752 |
2020 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
The Prospective comparison of Angiotensin Receptor-neprilysin inhibitor (ARNI) with Angiotensin converting enzyme inhibitor (ACEI) to Determine Impact on Global Mortality and morbidity in Heart Failure (HF) trial (PARADIGM-HF) showed that adding a neprilysin inhibitor (sacubitril) to a renin-angiotensin system blocker (and other standard therapy) reduced morbidity and mortality in ambulatory patients with chronic HF with reduced ejection fraction (HFrEF).
|
31172710 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Prescription of recommended HF drugs was low: 42.6% (629) used Angiotensin Converting Enzyme Inhibitors (ACEI) or Angiotensin Receptor Blockers (ARBs), 48.0% (709) β-blockers, and 21.9% (324) ACEI or ARB with β-blockers, even in reduced LVEF.
|
31370798 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Recently, the addition of neprilysin inhibition to angiotensin receptor blockade has been shown to be even more effective than angiotensin-converting enzyme inhibition alone in heart failure with reduced ejection fraction, marking an important new milestone in heart failure treatment.
|
31370961 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Angiotensin-converting enzyme inhibitors were more protective in the advancement and/or hospitalization of the hypertensive patient for heart failure than angiotensin receptor blockers.
|
30518809 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
The target of the current study was to examine the possible cardioprotective effect of telmisartan (Tel), an angiotensin II type 1 receptor (AT1R) blocker, compared with that of captopril (Cap), an angiotensin converting enzyme (ACE) inhibitor, in ameliorating PRG-induced HF in rats by assessing morphometric, echocardiographic and histopathological parameters.
|
31629013 |
2019 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Using the 2008-2012 IBM MarketScan Commercial database, we followed 26,439 individuals aged 18-64 years with newly diagnosed HF and calculated their adherence (using the proportion of days covered (PDC) algorithm) to the five guideline-recommended medication categories: angiotensin-converting enzyme inhibitors/angiotensin-receptor blockers; beta blockers; aldosterone receptor antagonists; hydralazine; and isosorbide dinitrate.
|
31545830 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Multivariate analysis revealed that several variables (including gender, hypertension, renal dysfunction, TIMI flow grade post-PCI < 3, and treatment administered after PCI with betablockers and angiotensin-converting enzyme inhibitors) had per se a significant influence on the occurrence of [death or hospitalization for heart failure] at 1 year.
|
31832789 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Most estimates revealed no effectiveness differences between classes; however, thiazide or thiazide-like diuretics showed better primary effectiveness than angiotensin-converting enzyme inhibitors: acute myocardial infarction (HR 0·84, 95% CI 0·75-0·95), hospitalisation for heart failure (0·83, 0·74-0·95), and stroke (0·83, 0·74-0·95) risk while on initial treatment.
|
31668726 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
There is currently no consensus on the effect of treatment with angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), on the prognosis of patients with heart failure and preserved ejection fraction (HFpEF).
|
30694579 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Angiotensin-converting enzyme inhibitors were more frequently prescribed in East Anatolia (52.3%, p=0.001), and the prevalence of patients with heart failure and preserved ejection fraction using loop diuretics (48.8%, p=0.003) was higher in the Black Sea region.
|
30945522 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Although angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) have been recommended for patients with heart failure, their clinical and prognostic impact in the very acute phase of acute heart failure (AHF) is unclear, mainly because data on their safety and efficacy are lacking.
|
31218508 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
The treatment of heart failure has changed with the use of angiotensin-converting enzyme inhibitors (ACEIs) and beta-blockers since the middle of the 1990s.
|
30876708 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Discharge treatment with ACE inhibitor/ARB after a HF hospitalisation is associated with a reduction in all-cause and refractory HF mortality, irrespective of LVEF.
|
30887642 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Heart Failure With Chronic Kidney Disease - Propensity Score Matching Analysis.
|
31776309 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Ninety-eight percent initially received standard heart failure therapy (beta-blockers, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and/or mineralocorticoid receptor antagonists), and 86% were additionally treated with dopamine D2 receptor agonists (mainly bromocriptine) and anticoagulation.
|
31724271 |
2019 |